Acceleron Pharma Inc.
ALK7 BINDING PROTEINS AND USES THEREOF
Last updated:
Abstract:
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
Status:
Application
Type:
Utility
Filling date:
26 Nov 2019
Issue date:
19 Mar 2020